Intellus Worldwide Summit 2020
We are delighted to be exhibiting at the virtual 2020 Intellus Worldwide Summit from 9th-10th June. Representing Research Partnership at the event will be Emily Hoffman, Associate Director.
Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19
Webinar: Thursday 25th June 15:00 BST /16:00 CEST /10:00 EDT
Register now for this live webinar event in which research experts Liza Pliss, Will Simpson and Emilie Braund will consider the impact the pandemic has and will continue to have on marketing in global healthcare and look at the continued shift towards digital communications as a means to engage physicians and patients.
Agile is a mind-set not a methodology
Thursday 18th June 2020 16:00SGT/ 16:00CEST/ 17:00JST
We’ve all heard about how important it is to be agile. And the focus in pharmaceutical market research has been mainly on speed, and the methodologies and techniques that get us faster results. But we believe there’s more to being agile than just toolkits and technology.
Research Partnership publishes new patient syndicated reports - Living with Severe & Eosinophilic Asthma US, Japan, 2EU
Living with severe & eosinophilic asthma is a new syndicated report which offers valuable insights into patient attitudes and behaviour. The EU study was conducted amongst 118 patients with diagnosis and/or confirmed characteristics of severe asthma (SA) or eosinophilic asthma (EA) in France and Germany. The US study was conducted with 105 SA and EA patients. For both studies the methodologies consisted of 30-minute quantitative online interviews and a small sample of 30-minute qualitative add-on telephone interviews. The Japan report will also be available to purchase over the coming weeks.
How we conducted rare disease patient research during the COVID-19 lockdown in China
Our client needed to conduct a small number of qualitative interviews in China with patients diagnosed with a rare condition which affects children and young adults. The results of the survey were time critical as they were needed to inform a protocol being published in 30 working days. We faced two key challenges, firstly to find, screen and recruit diagnosed patients with a prevalence of 0.9 per 100,000 and secondly to achieve this during the restrictions of the COVID-19 lockdown in 2020.